Tetraphase Pharmaceu (TTPH) 3.94 $TTPH Tetraphase

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 2:13 PM

Tetraphase Pharmaceu (TTPH) 3.94 $TTPH

Tetraphase Pharmaceuticals Announces Presentation of Data at ASM Microbe 2016
GlobeNewswire - Mon May 23, 7:30AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced seventeen data presentations at the American Society of Microbiology (ASM) Microbe 2016 Conference, taking place June 16-20 in Boston, MA. Presentations will include information about the company's lead drug candidate, eravacycline, as well as data from its TP-271 program.
TTPH: 3.94 (-0.17)

The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
Zacks Equity Research - Zacks Investment Research - Fri May 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Medivation, Anacor, Aduro, Trevena and Tetraphase
MDVN: 60.01 (-0.09), TTPH: 3.94 (-0.17), TRVN: 6.84 (-0.38), ADRO: 11.99 (-0.43), ANAC: 99.17 (+0.09)

Biotech Stock Roundup: Pfizer to Buy Anacor for $5.2B, Pipeline Setbacks for Aduro, Trevena
Arpita Dutt - Zacks Investment Research - Thu May 19, 2:36PM CDT
Key highlights in the biotech sector include the acquisition agreement between Anacor (ANAC) and Pfizer as well as data presentations.
MDVN: 60.01 (-0.09), TRVN: 6.84 (-0.38), TTPH: 3.94 (-0.17), VRTX: 91.49 (-1.00), ADRO: 11.99 (-0.43), AMGN: 154.78 (-2.00), ANAC: 99.17 (+0.09)

Nordstrom and Wal-Mart fall, Shake Shack and Nvidia jump
AP - Fri May 13, 3:36PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday:
TTPH: 3.94 (-0.17), SHAK: 34.95 (-2.83), WMT: 71.14 (+0.05), JWN: 38.88 (-0.69), CXR.TO: 30.35 (-0.77), NTK: 51.03 (-0.42), CXRX: 23.80 (-0.67), NVDA: 46.20 (-1.18)

Tetraphase Pharmaceuticals Provides Update on Eravacycline Regulatory and Development Status
GlobeNewswire - Thu May 12, 3:05PM CDT
- Additional phase 3 clinical trial in cIAI planned to support NDA filing -
TTPH: 3.94 (-0.17)

Tetraphase Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 3:30PM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the first quarter ended March 31, 2016.
TTPH: 3.94 (-0.17)

Buying Stocks: Investors Are Considering These on Thursday April 7
ACCESSWIRE - Thu Apr 07, 12:34PM CDT
MIAMI, FL / ACCESSWIRE / April 7, 2016 / Top Nasdaq Stocks is issuing a report on four stocks to watch. CANN, COOL, TTPH, and EKSO have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the Nasdaq/NYSE subscribe to our newsletter at TopNasdaqStocks.com.
TTPH: 3.94 (-0.17), COOL: 0.88 (unch)

Tetraphase Pharmaceuticals to Present Data at 26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
GlobeNewswire - Thu Apr 07, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced five data presentations at the 26 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place April 9-12 in Amsterdam, Netherlands. Presentations will include information about the company's lead drug candidate, eravacycline, as well as data from its preclinical TP-6076 program.
TTPH: 3.94 (-0.17)

Tetraphase Pharmaceuticals to Present at Needham Conference 2016
GlobeNewswire - Wed Apr 06, 7:00AM CDT
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate presentation at the 15 Annual Needham & Co. Healthcare Conference on Wednesday, April 13, 2016 at 11:20 a.m. Eastern Time at The Westin Grand Central Hotel in New York City.
TTPH: 3.94 (-0.17)

EQUITY UPDATE: Goldberg Law PC Files Securities Class Action Lawsuit against Tetraphase Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
BusinessWire - Fri Mar 25, 2:14PM CDT
Goldberg Law PC (www.Goldberglawpc.com) announces that it has filed a class action lawsuit against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, (the "Class Period"

, are encouraged to contact the firm in advance of the March 28, 2016, lead plaintiff motion deadline. The new lawsuit has been filed on behalf of options purchasers and sellers.
TTPH: 3.94 (-0.17)

IMPORTANT DEADLINE REMINDER: Khang & Khang LLP Announces The Filing Of A Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm
BusinessWire - Fri Mar 25, 9:50AM CDT
Khang & Khang LLP (the "Firm"

announces that a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(Nasdaq: TTPH). Investors who purchased or otherwise acquired shares between March 5, 2015 and September 8, 2015, inclusive (the "Class Period"

, are encouraged to contact the Firm prior to the March 28, 2016, lead plaintiff motion deadline.
TTPH: 3.94 (-0.17)

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Tetraphase Pharmaceuticals, Inc. and Lead Plaintiff Deadline: March 28, 2016
ACCESSWIRE - Fri Mar 25, 9:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 25, 2016 / Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a securities class action has been filed in the United States District Court for the District of Massachusetts on behalf of those who purchased shares of Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(NASDAQ: TTPH), during the period between March 5, 2015 and September 9, 2015 inclusive (the "Class Period"

.
TTPH: 3.94 (-0.17)

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of Tetraphase Pharmaceuticals Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 28, 2016 - TTPH
PR Newswire - Thu Mar 24, 1:47PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
TTPH: 3.94 (-0.17)

EQUITY ALERT UPDATE: Rosen Law Firm Expands Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. on Behalf of Options Purchasers and Sellers
BusinessWire - Wed Mar 23, 6:07PM CDT
Rosen Law Firm, a global investor rights law firm, has filed a class action lawsuit on behalf of all purchasers of the common stock and call options and sellers of put options of Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) from March 5, 2015 through September 8, 2015, all dates inclusive (the "Class Period"

. The lawsuit seeks to recover damages for Tetraphase Pharmaceuticals investors under the federal securities laws.
TTPH: 3.94 (-0.17)

Lifshitz & Miller Law Firm Announces Investigation of comScore, Inc., LendingClub Corporation, Rockwell Medical, Inc., ROFIN-SINAR Technologies, Inc., Tailored Brands, Inc., Tangoe, Inc., and Tetraphase Pharmaceuticals, Inc.
PR Newswire - Tue Mar 22, 8:01PM CDT
comScore, Inc. (SCOR)
TTPH: 3.94 (-0.17), TNGO: 7.93 (-0.08), LC: 4.26 (-0.21), TLRD: 11.60 (-0.74), RSTI: 31.84 (-0.03), RMTI: 8.85 (-0.56), SCOR: 31.32 (-0.80)

INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. and Reminds Investors with Losses to Contact the Firm
BusinessWire - Tue Mar 22, 12:13PM CDT
Lundin Law PC announces a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(NASDAQ: TTPH) concerning possible violations of federal securities laws between March 5, 2015 and September 8, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the March 28, 2016, lead plaintiff motion deadline.
TTPH: 3.94 (-0.17)

INVESTOR ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Lawsuit Involving Tetraphase Pharmaceuticals Inc. and a Lead Plaintiff Deadline of March 28, 2016 - TTPH
GlobeNewswire - Tue Mar 22, 10:09AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) securities between March 5, 2015 and September 8, 2015.
TTPH: 3.94 (-0.17)

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Tetraphase Pharmaceuticals, Inc. And Reminds Investors With Losses To Contact The Firm
BusinessWire - Fri Mar 18, 9:38PM CDT
Lundin Law PC announces a class action lawsuit has been filed against Tetraphase Pharmaceuticals, Inc. ("Tetraphase" or the "Company"

(NASDAQ: TTPH) concerning possible violations of federal securities laws between March 5, 2015 and September 8, 2015. Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm in advance of the March 28, 2016, lead plaintiff motion deadline.
TTPH: 3.94 (-0.17)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Tetraphase Pharmaceuticals Inc. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 28, 2016 - TTPH
GlobeNewswire - Fri Mar 18, 2:00PM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
TTPH: 3.94 (-0.17)

Anthrax Market Pipeline Global Review Research Report for H2 2015
PR Newswire - Thu Mar 17, 9:00PM CDT
The "Anthrax - Pipeline Review, H2 2015" market research report provides an overview of the Anthrax's therapeutic pipeline and helps enhance decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
DVAX: 14.59 (-0.46), TTPH: 3.94 (-0.17), ADRO: 11.99 (-0.43), EBS: 42.30 (-1.19), UTHR: 111.35 (-1.78), BMY: 72.65 (-0.08), PFNX: 7.52 (+0.09), PIP: 2.16 (-0.02), IBIO: 0.61 (-0.02), OGEN: 0.65 (+0.02)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

NatGold Pulling NATG From MEXC Amid Security Concerns

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

Boston STEM Expo Sparks Young Minds in Engineering

If you really want to light up a kid's imagination, throw them into a room full of science experiments and let 'em have at it. That's exactly what happened at the recent Society of Women Engineers' Innovation Expo in Boston's Seaport District. The place was buzzing, and not just because of all the engineering gadgets on display—it was the energy of young minds...

Historic Records Set at 2026 CNO Monumental Marathon

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Evaluating GLP-1 Telehealth? Key Questions to Consider

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

Johnson & Johnson Unveils Promising PsA Treatment Data

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Quantum Space Joins $185M NASA Lunar Transport Deal

Quantum Space Bags a Chunk of NASA's Lunar Ambitions Alright, folks, buckle up because we're about to dive into the cosmos. Quantum Space just nabbed a sweet deal—a $185 million whopper of a contract from NASA's Moon Base Transportation program. This isn't chump change; it's a 25% slice for Quantum from the lot Arrow Science and Technology is heading. We're talking...

Off-Broadway Play 'DUST' Raises Autism Support Funds

Here's the scoop: an Off-Broadway production just did something many big hitters can't pull off. 'DUST,' a show crafted like a love letter to the American West, managed to rustle up $30,000 for young adults grappled with autism. Partnering with no less than Yale's Cultural Autism Studies and the Ed Asner Family Center, this effort hit the mark in more ways than one. An...